Welcome to our dedicated page for Korro Bio SEC filings (Ticker: KRRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Korro Bio, Inc. filings document the regulatory record of a biopharmaceutical company developing RNA-editing genetic medicines through its OPERA® platform. Its 8-K reports disclose operating and financial results, corporate presentations, clinical and regulatory program updates, capital-structure activity, and material events tied to its RNA-editing pipeline.
The company’s filings also cover proxy governance, executive compensation, equity incentive and inducement arrangements, employment agreements, and material collaboration and license agreements. Program-related disclosures focus on KRRO-121, hyperammonemia in urea cycle disorders and hepatic encephalopathy, GalNAc-conjugated oligonucleotide research, alpha-1 antitrypsin deficiency, risk factors, and the financing and governance framework supporting Korro Bio’s development-stage operations.
Korro Bio, Inc. reported that Senior Vice President of Finance Dolan Oliver received a stock option award. On February 2, 2026, Oliver was granted an option to buy 15,000 shares of Korro Bio common stock at an exercise price of $13.05 per share, expiring February 1, 2036.
The option vests in 48 equal monthly installments starting February 2, 2026, contingent on Oliver’s continued service with the company on each vesting date. After this grant, Oliver beneficially owns 15,000 derivative securities directly.
Korro Bio, Inc. reported that its General Counsel, Jeffrey Cerio, received a grant of stock options covering 23,000 shares of common stock. The options have an exercise price of $13.05 per share and were awarded on February 2, 2026.
These options vest in 48 equal monthly installments starting on February 2, 2026, and each vesting date requires Mr. Cerio to remain in service with the company. Following this grant, he beneficially holds options for 23,000 shares, all in direct ownership.
Korro Bio, Inc. reported that Chief Operating Officer Todd Chappell received a stock option award for 38,000 derivative securities described as a stock option (right to buy) common stock. The option has an exercise price of $13.05 per share and was granted on February 2, 2026.
The grant was made for no purchase price and leaves Chappell with 38,000 stock options beneficially owned directly. These options expire on February 1, 2036 and vest in 48 equal monthly installments starting February 2, 2026, conditioned on his continued service at each vesting date.
The Vanguard Group has filed a Schedule 13G reporting a passive ownership stake in Korro Bio Inc. Vanguard reports beneficial ownership of 489,639 shares of Korro Bio common stock, representing 5.19% of the class as of the event date.
Vanguard lists shared voting power over 43,589 shares and shared dispositive power over 489,639 shares, with no sole voting or dispositive power. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Korro Bio.
Korro Bio, Inc. reported that it hosted a virtual Analyst Day on January 27, 2026. The company made selected presentation slides from this event publicly available by attaching them as an exhibit to this report. These slides are intended to provide additional background and strategic information about Korro Bio’s business for analysts and investors.
Korro Bio, Inc. filed a current report to note that it has updated its corporate presentation. On January 15, 2026, the company prepared new materials for use in meetings with investors, analysts, and other audiences, and filed selected updated slides as an exhibit. These slides, dated January 15, 2026, are incorporated by reference as part of the report, giving stakeholders an officially filed version of the latest overview of the company and its business.
Korro Bio updated the employment agreement for executive Jeffrey Cerio, effective December 15, 2025. His new agreement keeps most prior terms but raises his annual base salary to $425,000. It also increases his cash severance from six to nine months of salary if he is terminated without cause or resigns for good reason, and from nine to 12 months if this occurs within a change in control period.
As part of a broader employee appreciation and retention program, Dr. Cerio will receive a $100,000 cash bonus, paid in two equal installments on December 31, 2025 and on or about June 30, 2026, subject to continued service. He was also granted 41,902 restricted stock units under Korro’s 2023 Stock Option and Incentive Plan, vesting 50% on June 15, 2026 and 50% on December 15, 2026, contingent on continued service through each vesting date.
Korro Bio, Inc. (KRRO) granted its chief operating officer 20,132 restricted stock units linked to its common stock. These RSUs were acquired at a reported price of $0.00 and leave the officer beneficially owning 20,132 shares directly after the transaction. The award was made under the company’s 2023 Stock Option and Incentive Plan and will vest in two equal installments: 50% on June 15, 2026 and 50% on December 15, 2026, provided the officer maintains a continuous Service Relationship through each vesting date.
Korro Bio's Chief Scientific Officer received a grant of 21,715 shares of common stock on December 15, 2025, reported as an acquisition at a price of $0.00 per share. Following this transaction, the officer beneficially owns 21,715 shares directly.
The shares are issuable upon settlement of a restricted stock unit (RSU) award granted under the company’s 2023 Stock Option and Incentive Plan. The RSUs will vest in two equal installments: 50% on June 15, 2026 and 50% on December 15, 2026, provided the officer maintains a continuous Service Relationship through each vesting date.
Korro Bio, Inc. reported an equity award to its General Counsel in an insider ownership filing. Officer Jeffrey Cerio acquired 41,902 shares of common stock at a price of $0.00, reflecting a grant tied to restricted stock units under the company’s 2023 Stock Option and Incentive Plan.
The filing explains that these shares are issuable upon settlement of a restricted stock unit (RSU) award that will vest in two equal installments: 50% on June 15, 2026 and 50% on December 15, 2026, if he maintains a continuous service relationship through each vesting date. After this grant, he is shown as beneficially owning 41,902 shares directly.